Cerus

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cerus excels in Q4 with record growth and strategic milestones

Cerus delivered a strong performance in Q4 2022, driven by the success of the INTERCEPT Blood System and robust product revenue growth.
While facing challenges in inventory management and international expansion, the company's focus on innovation and upcoming milestones position it for future growth.
Opportunities in regulatory submissions, market expansion, and achieving cash flow breakeven in 2023 underscore Cerus' potential for sustained success and market leadership.

Cerus reports Q1 revenue dip, eyes China growth opportunities

Cerus navigated Q1 with a focus on financial stability, product adoption, and global market expansion. Despite revenue challenges, the company's strategic initiatives and successful debt refinancing position it for future growth. Addressing inventory management, label expansion, and market-specific hurdles will be key to unlocking opportunities.

Cerus (CERS) reports robust Q2 performance amidst growth challenges

Cerus delivered a strong performance in Q2, marked by revenue growth, improved margins, and effective cost management.
While facing challenges in U.S. customer ordering patterns and market penetration, the company remains well-positioned for growth.
With a focus on operational efficiency, product development, and market expansion, Cerus is poised to capitalize on growth opportunities.
The company's financial strength, coupled with strategic initiatives, sets a positive trajectory for continued progress and success.

Cerus reports robust Q3 sales, adjusts revenue guidance for 2023

Cerus shows strong sales growth, positive market sentiment, and progress in key trials. Challenges include revenue guidance adjustment due to delayed sales agreement. Opportunities lie in expanding product demand and achieving EBITDA breakeven.

Cerus surpasses 16 million kits sold, expects double-digit growth

Cerus delivered a strong performance in Q4 2023, surpassing 16 million kits sold and achieving positive non-GAAP adjusted EBITDA for the first time.
The company's focus on the platelet franchise and IFC business yielded growth, setting the stage for continued expansion in 2024.
While facing challenges in revenue expectations and market competition, Cerus remains well-positioned to capitalize on growth opportunities.
Guidance for 2024 indicates a positive outlook with expectations of sustained growth in the INTERCEPT platelet business and IFC revenue.

Cerus reports robust Q1 earnings, eyes international growth opportunities

Cerus' Q1 2024 earnings call highlighted strong financial performance, positive trial results, and reiterated revenue guidance. The company is focused on achieving breakeven non-GAAP adjusted EBITDA for the year. Challenges include regulatory progress and working capital adjustments, while opportunities exist in international market expansion and operational optimization.

Cerus excels in Q2 2024, raises revenue guidance amid global expansion

Cerus demonstrates strong financial performance, driven by global adoption of INTERCEPT. Focus on expanding sales in key markets and addressing analyst queries to sustain growth momentum. Future growth prospects look promising with a commitment to transparency and investor engagement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amazon

Alibaba

MercadoLibre

Pinduoduo Inc - ADR

According to the GuruFocus Scoreboard, where users can sort investing gurus based on their fund performances over specific periods of time, the gurus that posted the highest gains during the most recent year were Catherine Wood (Trades, Portfolio) and Ron Baron (Trades, Portfolio). For full-year 2020, Wood's Ark Investment Management returned 152.50%, while Ron Baron (Trades, Portfolio)'s Baron Funds gained 148.50%.

Undervalued Stocks That Catherine Wood and Ron Baron Agree On

CONCORD, Calif.--(BUSINESS WIRE)--Today marks the effective date for the U.S. Food and Drug Administration's (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion. This guidance for industry, “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelet for Transfusion,” which was finalized in 2020, identifies FDA-approved pathogen reduction as a means of com

Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021. On Thursday, September 23, Cerus will host an industry workshop, “Clinical need for and experience with the new Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex),” from 1:00-1:30p.m. EDT featuring two hospital customers currently us

Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021

Cerus Corporation once again reports record growth, however, the market has throttled any momentum in the share price. Despite the lackluster price action, I remain bullish on CERS. The FDA compliance date in October is quickly approaching. It is possible we see a significant inflection point in INTERCEPT sales in the coming quarters.

Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m. ET. A live webcast of the presentation will be available on Cerus' Investor Relations page at http://www.cerus.com/ir. A replay of the webcast will be availa

Cerus Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for Pathogen Reduced Cryoprecipitated Fibrinogen Complex, or INTERCEPT Fibrinogen Complex (IFC), and Pathogen Reduced Plasma, Cryoprecipitate Reduced. These new P-codes, P9026 and P9025, respectively, are effective October 1, 2021. “By providing a means for hospit

Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center (SRRMC), to its Board of Directors. SRRMC, a 123-bed acute care hospital located in the East Bay Area, is part of a joint venture involving Tenet Healthcare. She also serves as the chairperson of the board overseeing the joint venture between John Muir Health and San Ramon Regional Medical Center. “We are delighted to welcome Ann to Cerus' Bo

Cerus Corporation Announces Appointment of Ann Lucena to Board of Directors

The stock price of Cerus Corporation (NASDAQ: CERS) increased by over 13% pre-market. This is why it happened.

CERS Stock Price Increases Over 13% Pre-Market: Why It Happened

Cerus Corporation (NASDAQ: CERS) reported second-quarter sales of $37.8 million, +41% Y/Y in line with the consensus. Product revenue reached $31.5 million, compared to $21.5 million a year ago, benefited from increased demand for INTERCEPT platelet products in the U.S.

Cerus Stock Gains As Q2 Earnings Match Expectations, Raises FY21 Sales Guidance

Cerus Corporation (CERS) CEO Obi Greenman on Q2 2021 Results - Earnings Call Transcript

Shares of Cerus (NASDAQ:CERS) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.09), which were in line with the estimate of ($0.09).

Recap: Cerus Q2 Earnings

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2021. Recent developments and highlights include: Second quarter 2021 total revenue of $37.8 million, reflecting a 41% increase over the prior year period. Total revenue was composed of (in thousands, except %):     Three Months Ended               Six Months Ended             June 30,               June 30,         (in thousands, except percentages)   2021

Cerus Corporation Announces Record Second Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System (IPPS). The NTAP was granted under CMS' alternative NTAP pathway, which recognizes the transformative nature of products granted Breakthrough Device designation by the U.S. Food and Drug Administration

Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cerus (CERS) Q2 Earnings Expected to Decline

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2021 financial results will be released on Tuesday, August 3, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the

Cerus Corporation to Release Second Quarter 2021 Financial Results on August 3, 2021

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS), a company solely dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blutspende SRK Schweiz) announced today the tenth anniversary of the use of the INTERCEPT Blood System for its entire platelet supply in Switzerland. “We are honored to mark the tenth anniversary of the routine use of INTERCEPT platelets with our long-time partners at the Swiss Red Cross,” stated William ‘Obi'

Cerus Corporation and the Swiss Red Cross Celebrate 10 Years of Routine Use of INTERCEPT Blood System for Platelets

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT® Fibrinogen Complex, the company's pathogen reduced cryoprecipitated fibrinogen complex product. LifeSouth is the fifth production partner for INTERCEPT Fibrinogen Complex, enabling the initial commercial launch of the product to expand into the state of Florida. “We are delighted to add LifeSouth as a b

Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manufacture INTERCEPT® Fibrinogen Complex

Cerus Corporation continues to record growth, however, the market continues to overlook the company's progress and upside potential.

Cerus Corp.: Market Continues To Overlook Growth And Upside Potential

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS), a leader in safeguarding the global blood supply, is proud to announce its celebration of this year's World Blood Donor Day. World Blood Donor Day, first established by the World Health Organization in 2005, highlights the critical role safe blood and blood products play in treating a wide variety of patients throughout the world and recognizes the donors who help make these products regularly available. As blood centers compet

Cerus Corporation Celebrates World Blood Donor Day 2021

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced its contract with Canadian Blood Services for the INTERCEPT Blood System for Platelets. Canadian Blood Services is one of Canada's two blood operators, serving all Canadian provinces and territories except Quebec. “Today's announcement is a significant milestone for Cerus as we enter the Canadian market. We are proud to partner with Canadian Blood Services to introduce pathogen inactivated platelets in Canada,” sa

Cerus Corporation Announces Contract with Canadian Blood Services for INTERCEPT Blood System for Platelets

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2021 Results - Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2021. Recent developments and highlights include: First quarter 2021 total revenue of $29.6 million, reflecting a 20% increase over the prior year period. Total revenue was composed of (in millions, except %):           Three Months Ended             March 31,               2021     2020   Change       Product revenue   $ 23.4   $ 18.6   26 %       Governmen

Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2021 financial results will be released on Tuesday, May 4, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inve

Cerus Corporation to Release First Quarter 2021 Financial Results on May 4, 2021

Cerus Corp. reported a record year with strong commercial growth and several pipeline wins. The company expects 2021 to be another record year.

Cerus Corp.: Remaining Bullish Despite Delayed Compliance Date

Kosmos Energy

Truecar Inc

LiveXLive Media

PennantPark Investment

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for Cerus Stock (CERS)